Cover Image
市場調查報告書

皮膚疾病治療藥的全球市場:2017年∼2027年的預測

Dermatological Drugs Market Forecast 2017-2027: Psoriasis, Skin Infection, Acne, Dermatitis, Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen, Elocon, Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer, LEO Pharma

出版商 Visiongain Ltd 商品編碼 233143
出版日期 內容資訊 英文 295 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
皮膚疾病治療藥的全球市場:2017年∼2027年的預測 Dermatological Drugs Market Forecast 2017-2027: Psoriasis, Skin Infection, Acne, Dermatitis, Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen, Elocon, Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer, LEO Pharma
出版日期: 2017年07月06日 內容資訊: 英文 295 Pages
簡介

全球皮膚疾病治療藥的市場在2016年寫下256億5000萬美元的記錄,預測在調查期間前半部分將以4.5%的年複合成長率(CAGR)成長。

本報告提供全球皮膚疾病治療藥的市場調查,提供皮膚醫學概要,一般的皮膚疾病種類與概要,各疾病種類的治療藥市場最新趨勢,市場規模的變化與預測,主要的治療藥簡介,主要地區以及各國趨勢,開發平台趨勢,並彙整主要企業的簡介等資訊。

第1章 報告概要

第2章 皮膚疾病治療藥:簡介

  • 醫藥品產業:概要
  • 皮膚醫學概要
    • 皮膚·毛髮·指甲結構
    • 毛髮和指甲
    • 汗腺和脂肪腺
    • 皮膚功能
  • 一般的皮膚疾病
    • 痤瘡 (粉刺):最常見的皮膚疾病
    • 皮膚炎:皮膚的發炎
      • 異位性皮膚炎
      • 接觸性皮膚炎 (CD)
      • 脂漏性皮膚炎
      • 錢幣型濕疹
      • 口周皮膚炎
    • 乾癬:複雜的多因素性疾病
    • 酒糟:血管不穩定
    • 脫髮症:異常頭髮脫落
  • 皮膚感染:嚴重的健康上威脅
    • 細菌性皮膚感染
    • 菌性皮膚感染
    • 病毒性皮膚感染
  • 一般的皮膚疾病治療藥
    • 乳霜·半固態乳劑
    • 軟膏
    • 化妝水
    • 液劑
    • 密封療法
    • 化學清潔劑
    • 粉末·親水性聚合物
    • 抗感染疾病劑
    • 抗發炎劑
  • 臨床試驗的階段
  • 皮膚疾病治療藥:本報告書的市場定義

第3章 全球皮膚疾病治療藥市場預測

  • 市場概要
  • 皮膚疾病治療藥的類別區分
  • 市場實際成果
  • 市場預測
  • 各部門的市場佔有率的預測

第4章 乾癬治療藥市場分析·預測

  • 乾癬治療藥:主流的生技藥品
    • 主要產品
  • 市場趨勢·發展趨勢
  • 市場預測
  • 主要藥物
    • Humira (Adalimumab:Abbott)
    • Stelara (Ustekinumab:Johnson & Johnson)
    • Enbrel (Etanercept:Amgen·Pfizer·武田藥品工業)
    • Remicade (Infliximab:Johnson & Johnson)
    • Taltz (Ixekizumab:Eli Lily)
    • Otezla (Apremilast:Celgene)
    • Cosentyx (Secukinumab:Novartis)
    • 其他
  • 摘要

第5章 皮膚感染疾病治療藥市場分析·預測

  • 皮膚感染治療藥:豐富的成長機會
    • 主要產品
  • 市場預測
  • 主要藥物
    • Cubicin(daptomycin:Cubist Pharmaceuticals·Merck & Co)
    • Acquisition(Merck & Co)
    • Cubicin與學名藥的競爭
    • Cubicin:銷售額預測
    • Cubicin:生命週期管理上策略
  • Zyvox (linezolid:Pfizer)
  • Canesten (Clotrimazole:Bayer)
  • Valtrex (valaciclovir:GSK)
  • Bactroban (mupiroshin:GSK)
  • Lamisil (Terbinafine:Novartis)
  • 其他
  • 摘要

第6章 痤瘡治療藥市場分析·預測

  • 痤瘡治療藥:多樣化的市場
    • 主要產品
  • 近幾年趨勢·發展趨勢
  • 市場預測
  • 主要藥物
    • Epiduo (adapalene/benzoyl peroxide) - Galderma/ Nestlé Skin Health
    • Solodyn (minocycline) - Valeant
    • Claravis (isotretinoin) - Teva
    • Differin (adapalene) - Galderma/ Nestlé Skin Health
    • Absorica/Epuris (CIP-isotretinoin) - Cipher/Sun Pharma
    • Ziana (clindamycin/tretinoin) - Valeant Pharmaceuticals International
    • Doryx (doxycycline) - Actavis/Mayne Pharma
    • 其他
  • 摘要

第7章 皮膚炎治療藥市場分析·預測

  • 皮膚炎治療藥:學名藥的高(貴)的普及率
    • 主要產品
  • 市場預測
  • 主要藥物
    • Bepanthen (dexpanthenol)/ Bepanthol - Bayer
    • Elocon (mometasone) - Merck & Co
    • Protopic (tacrolimus) - LEO Pharma
    • Dermovate -GSK
    • 其他
  • 市場展望

第8章 主要國家市場預測

  • 各地區市場
  • 主要國家市場預測
    • 市場佔有率的變化與預測
  • 市場分析·預測:各地區
    • 美國
    • 歐盟5國
      • 德國
      • 法國
      • 英國
      • 義大利
      • 西班牙
    • 日本
    • 中國
    • 印度
    • 巴西
    • 俄羅斯
    • 其他

第9章 主要企業

  • 皮膚疾病治療藥:朝整合化發展的市場
  • Galderma
  • Johnson & Johnson
  • AbbVie
  • GlaxoSmithKline
  • Pfizer
  • LEO Pharma

第10章 研發產品線的預測

  • 正在開發的創新產品:今後的市場促進成長
  • 乾癬治療藥的開發平台
  • 皮膚感染疾病治療藥的開發平台
  • 痤瘡治療藥的開發平台
  • 皮膚炎治療藥的開發平台
  • 其他的治療藥物的開發平台

第11章 定性分析

  • 市場的影響因素
  • SWOT分析
  • 波特的五力分析

第12章 採訪概要

第13章 總論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0209

The revenue of the dermatological drugs market in 2016 is estimated at $25.65bn and is expected to grow at a CAGR of 4.5% in the first half of the forecast period. Psoriasis drugs accounted for the largest share of the market in 2016, this segment generated $9.23bn.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 295-page report you will receive 111 tables and 92 figures - all unavailable elsewhere.

The 295-page report provides clear detailed insight into the dermatological drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Dermatological drugs market forecasts from 2017-2027
  • This report also breaks down the revenue forecast for the main submarkets:
    • Psoriasis
    • Skin Infections
    • Acne
    • Dermatitis
  • Analysis of the Psoriasis drugs market. Revenue forecasts to 2027 are provided for the following drugs:
    • Humira
    • Stelara
    • Enbrel
    • Remicade
    • Taltz
    • Otezla
    • Cosentyx
  • Analysis of the Skin Infections drugs market. Revenue forecasts to 2027 are provided for the following drugs:
    • Cubicin
    • Zyvox
    • Valtrex
    • Canesten
    • Lamisil
    • Bactroban
  • Analysis of the Acne drugs market. Revenue forecasts to 2027 are provided for the following drugs:
    • Solodyn
    • Epiduo
    • Claravis
    • Aczone
    • Differin
    • Abscorical/Epirus
    • Ziana
    • Doryx

image1

  • Analysis of the Dermatitis drugs market. Revenue forecasts to 2027 are provided for the following drugs:
    • Bepanthen/Bepanthol
    • Protopic
    • Dermovate
    • Elocon
  • This report provides individual revenue forecasts to 2027 for these regional and national markets:
    • US
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Japan
    • China
    • Brazil
    • Russia
    • India
    • Rest of World
  • This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.
  • Our study includes SWOT analysis and Porter's Five Force analysis of the dermatological drugs market.
  • Two interviews conducted by Visiongain with experts in the dermatological drugs market:
  • Interview with Dr Michael Siegel, Vice President of Research Programs at National Psoriasis Foundation
  • Interview with Guillaume Clement, Executive Vice President, Region EUROPE+, LEO Pharma
  • Our study discusses the selected leading companies that are the major players in the dermatological drugs market:
    • Galderma (Nestle Skin Health S.A.)
    • Johnson & Johnson
    • AbbVie
    • GlaxoSmithKline (GSK)
    • Pfizer
    • LEO Pharma

Our new report discusses issues and events affecting the dermatological drugs market:

  • Highly fragmented and competitive market with significant variations in different geographic regions
  • Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
  • Future paradigm-shifting pipeline products
  • Patent expirations
  • Launches of new drug categories
  • Biosimilars approvals, Biosimilars interchangeability, Biosimilars guidance

Visiongain's study is intended for anyone requiring commercial analyses for the dermatological drugs market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Global Dermatological Drugs: Market Overview
  • 1.2 Global Dermatological Drugs Market Segmentation
  • 1.3 Overview of Findings
  • 1.4 Structure of the Report
  • 1.5 Why You Should Read This Report
  • 1.6 How This Report Delivers
  • 1.7 Key Questions Answered by This Analytical Report
  • 1.8 Who is This Report For?
  • 1.9 Methodology
  • 1.10 Frequently Asked Questions (FAQ)
  • 1.11 Associated Visiongain Reports
  • 1.12 About Visiongain

2. An Introduction to Dermatological Drugs

  • 2.1 The Pharmaceutical Industry: A Brief Introduction
  • 2.2 An Introduction to Dermatology
    • 2.2.1 The Structure of Skin, Hair, and Nails
    • 2.2.2 Hair and Nails
    • 2.2.3 Sweat and Sebaceous Glands
    • 2.2.4 Functions of the Skin
  • 2.3 Common Skin Diseases
    • 2.3.1 Acne: The Most Common Skin Disease
      • 2.3.1.1 Acne: Epidemiology
      • 2.3.1.2 Acne: Causes and Pathogenesis
      • 2.3.1.3 Acne: Treatment
    • 2.3.2 Dermatitis: Inflammation of the Skin
      • 2.3.2.1 Atopic Dermatitis
      • 2.3.2.2 Contact Dermatitis
      • 2.3.2.3 Seborrhoeic Dermatitis
      • 2.3.2.4 Nummular Dermatitis
      • 2.3.2.5 Perioral Dermatitis
    • 2.3.3 Psoriasis: A Complex Multi-factorial Disease
    • 2.3.4 Rosacea: Vascular Instability
    • 2.3.5 Alopecia: Excessive Shedding Of Hair
  • 2.4 Skin Infections: A Serious Healthcare Threat
    • 2.4.1 Bacterial Skin Infections
    • 2.4.2 Fungal Skin Infections
    • 2.4.3 Viral Skin Infections
  • 2.5 Common Skin Treatments
    • 2.5.1 Creams and Semisolid Emulsions
    • 2.5.2 Ointments
    • 2.5.3 Lotions
    • 2.5.4 Solutions
    • 2.5.5 Occlusive Therapy
    • 2.5.6 Cleansing Agents
    • 2.5.7 Powders and Hydrophilic Polymer
    • 2.5.8 Anti-Infective Agents
    • 2.5.9 Anti-Inflammatory Agents
  • 2.6 Phases of Clinical Trials
  • 2.7 Dermatological Drugs: Market Definition in this Report

3. The Global Dermatological Drugs Market, 2017-2027

  • 3.1 The Global Dermatological Drugs Market: Market Overview
  • 3.2 Categorisation of the Global Dermatological Drugs Market
  • 3.3 The Global Dermatological Drugs Market in 2016
  • 3.4 The Global Dermatological Drugs Market: Market Forecast 2017-2027
  • 3.5 Dermatological Drugs: Changing Market Shares by Sector 2017-2027

4. The Psoriasis Drugs Market: Market Analysis and Forecast 2017-2027

  • 4.1 Psoriasis Treatments: The Dominance of Biologics
    • 4.1.1 Leading Products in the Psoriasis Drugs Market, 2016
  • 4.2 Psoriasis: Market Trends and Developments, 2017
    • 4.2.1 Biological Drugs in Psoriasis Treatment: A Brief Overview
    • 4.2.2 Issues around Patent Protection, the Threat of Biosimilars and Pricing
    • 4.2.3 Biosimilars and Interchangeables
      • 4.2.3.1 Extrapolation of indications
      • 4.2.3.2 Biosimilar interchangeability in the EU
      • 4.2.3.3 Biosimilar guidance in the US
    • 4.2.4 The Disadvantages of Biologics in Psoriasis Treatment
  • 4.3 Psoriasis Drugs: Market Forecast 2017-2027
    • 4.3.1 Psoriasis Drugs: Changing Market Shares by Leading Drugs 2016-2027
  • 4.4 Leading Drugs Used in the Treatment of Psoriasis
    • 4.4.1 Humira (adalimumab) - AbbVie
      • 4.4.1.1 Humira: Historical Sales Analysis, 2010-2015
      • 4.4.1.2 Humira: Sales Forecast 2017-2027
      • 4.4.1.3 Future Prospects for Biosimilar Versions of Humira
    • 4.4.2 Stelara (ustekinumab) - Johnson & Johnson
      • 4.4.2.1 Stelara New Market Leader, Ahead of Humira
      • 4.4.2.2 Stelara: Historical Sales Analysis, 2010-2015
      • 4.4.2.3 Stelara: Sales Forecast 2017-2027
      • 4.4.2.4 Intensifying Competition for Stelara
    • 4.4.3 Enbrel (etanercept) - Amgen/ Pfizer/ Takeda
      • 4.4.3.1 Enbrel: Co-Promotions and Marketing Rights
      • 4.4.3.2 Enbrel: Historical Sales Analysis, 2008-2016
      • 4.4.3.3 Enbrel: Patent Expiries and Potential Competition, 2017-2027
      • 4.4.3.4 Patent Litigation with Sandoz Over Enbrel
      • 4.4.3.5 Enbrel: Sales Forecast 2017-2027
      • 4.4.3.6 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years
      • 4.4.3.7 Competition from Other Drugs
      • 4.4.3.8 Biosimilar Competition for Enbrel
    • 4.4.4 Remicade (infliximab) - Johnson & Johnson
      • 4.4.4.1 Remicade: Historical Sales Analysis, 2008-201
      • 4.4.4.2 Remicade: Patent Expiries and Potential Competition, 2017-2027
      • 4.4.4.3 Remicade: Sales Forecast 2017-2027
    • 4.4.5 Taltz (ixekizumab) - Eli Lily
      • 4.4.5.1 Taltz: Sales Forecast 2017-2027
    • 4.4.6 Otezla (apremilast) - Celgene
      • 4.4.6.1 Otezla: Sales Forecast 2017-2027
    • 4.4.7 Cosentyx (secukinumab) - Novartis
      • 4.4.7.1 Cosentyx: Sales Forecast 2017-2027
    • 4.4.8 Other Psoriasis Drugs
      • 4.4.8.1 Cimzia (certolizumab) - UCB
      • 4.4.8.2 Sorilux (calcipotriene foam) - GSK
      • 4.4.8.3 Siliq (brodalumab) - AstraZeneca/ LEO Pharma
      • 4.4.8.3 Other Psoriasis Drugs: Sales Forecast 2017-2027
  • 4.5 Psoriasis Drugs Market: Summary

5. Skin Infection Drugs Market: Market Analysis and Forecast 2017-2027

  • 5.1 Skin Infection Drugs: Abundant Growth Opportunities
    • 5.1.1 Leading Products in the Skin Infection Drugs Market, 2016
  • 5.2 Skin Infection Drugs: Market Forecast 2017-2027
    • 5.2.1 Skin Infection Drugs: Changing Market Shares by Leading Drugs 2017-2027
  • 5.3 Leading Drugs Used in the Treatment of Skin Infections
    • 5.3.1 Cubicin (daptomycin) - Cubist Pharmaceuticals/ Merck & Co
    • 5.3.2 Acquisition by Merck & Co
    • 5.3.3 Generic Competition for Cubicin
    • 5.3.4 Cubicin: Sales Forecast 2017-2027
    • 5.3.5 Lifecycle Management Strategies for Cubicin
  • 5.4 Zyvox (linezolid) - Pfizer
    • 5.4.1 Zyvox: Historical Sales Analysis, 2010-2015
    • 5.4.2 Zyvox: Sales Forecast 2017-2027
    • 5.4.3 The Threats to Zyvox Sales from Competing New Drugs
  • 5.5 Canesten (clotrimazole) - Bayer
    • 5.5.1 Canesten: Historical Sales Analysis, 2011-2015
    • 5.5.2 Canesten: Sales Forecast 2017-2027
  • 5.6 Valtrex (valaciclovir) - GSK
    • 5.6.1 Valtrex: Historical Sales Analysis, 2010-2015
    • 5.6.2 Valtrex: Sales Forecast 2017-2027
  • 5.7 Bactroban (mupirocin) - GSK
    • 5.7.1 Bactroban: Historical Sales Analysis, 2010-2013
    • 5.7.2 Bactroban: Sales Forecast 2017-2027
  • 5.8 Lamisil (terbinafine) - Novartis
    • 5.8.1 Lamisil Patent Expiry
    • 5.8.2 Lamisil Sales Affected By Novartis Manufacturing Problems
    • 5.8.3 Lamisil: Sales Forecast 2017-2027
  • 5.9 Other Skin Infection Drugs
    • 5.9.1 Dalvance (dalbavancin) - Durata Therapeutics
    • 5.9.2 Jublia (efinaconazole) - Valeant
    • 5.9.3 Kerydin (tavaborole) - Anacor
    • 5.9.4 Sivextro (tedizolid) - Cubist Pharmaceuticals
    • 5.9.5 Zovirax (acyclovir) - Valeant/GSK
    • 5.9.5.1 Valeant Acquires Zovirax in US and Canada
    • 5.9.5.2 Mylan's Generic Zovirax and Actavis' Authorised Generic
    • 5.9.6 Other Skin Infection Drugs: Sales Forecast 2017-2027
  • 5.10 Skin Infection Drugs: Market Summary

6. Acne Drugs Market: Market Analysis and Forecast 2017-2027

  • 6.1 Acne Drugs: A Diversified Market
    • 6.1.1 Leading Products in the Acne Drugs Market, 2016
  • 6.2 Acne Drugs Market: Recent Trends and Developments
    • 6.2.1 The Rise of Combination Therapies in Acne Treatment
    • 6.2.2 Oral Contraceptives in Treating Acne
    • 6.2.3 The Threat of Generic Competition in the Acne Drugs Market
  • 6.3 Acne Drugs: Market Forecast 2017-2027
    • 6.3.1 Acne Drugs: Changing Market Shares by Leading Drugs 2016-2027
  • 6.4 Leading Drugs in the Acne Drugs Market
    • 6.4.1 Epiduo (adapalene/benzoyl peroxide) - Galderma/ Nestlé Skin Health
      • 6.4.1.1 Epiduo: Sales Forecast 2017-2027
      • 6.4.1.2 Galderma Settlement Agreement over Generic Epiduo
      • 6.4.1.3 Paediatric Approval for Epiduo
    • 6.4.2 Solodyn (minocycline) - Valeant
      • 6.4.2.1 Solodyn: Sales Forecast 2017-2027
      • 6.4.2.2 Antitrust Action over Solodyn Pay-For-Delay Deals
      • 6.4.2.3 Impax and Medicis Collaborating On Advanced Solodyn
      • 6.4.2.4 Medicis and Lupin Settle
    • 6.4.3 Claravis (isotretinoin) - Teva
      • 6.4.3.1 Claravis: Sales Forecast 2017-2027
    • 6.4.4 Aczone (dapsone) - Allergan
      • 6.4.4.1 Aczone: Sales Forecast 2017-2027
    • 6.4.5 Differin (adapalene) - Galderma/ Nestlé Skin Health
      • 6.4.5.1 Recent Generic Competition to Differin
      • 6.4.5.2 Differin: Sales Forecast 2017-2027
      • 6.4.5.3 Adapalene Gel to be Available OTC in the US
      • 6.4.5.4 Federal Circuit Court Invalidates Differin Patents
    • 6.4.6 Absorica/Epuris (CIP-isotretinoin) - Cipher/Sun Pharma
      • 6.4.6.1 Absorica/Epuris: Sales Forecast 2017-2027
    • 6.4.7 Ziana (clindamycin/tretinoin) - Valeant Pharmaceuticals International
      • 6.4.7.1 Valeant's Patent Settlement with Actavis over Ziana
      • 6.4.7.2 Ziana: Sales Forecast 2017-2027
    • 6.4.8 Doryx (doxycycline) - Actavis/Mayne Pharma
      • 6.4.8.1 Lifecycle Management Strategies for Doryx
      • 6.4.8.2 Divestment Agreement with Mayne Pharma
      • 6.4.8.3 Generic Competition for Doryx
      • 6.4.8.4 Doryx: Sales Forecast 2017-2027
    • 6.4.9 Other Acne Drugs
      • 6.4.9.1 Acanya (clindamycin/benzoyl peroxide) - Dow / Valeant
        • 6.4.9.1.1 Actavis Claims First-to-File Exclusivity for its Acanya ANDA
        • 6.4.9.1.2 Legal Battles Involving Dow/Valeant, Perrigo, and Watson
      • 6.4.9.2 Amnesteem (isotretinoin) - Mylan
        • 6.4.9.2.1 Amnesteem: Financial Analysis
      • 6.4.9.3 Diane (cyproterone/ethinyl estradiol) - Bayer
      • 6.4.9.4 Duac (clindamycin/benzoyl peroxide) - GlaxoSmithKline
      • 6.4.9.5 Veltin (tretinoin/clindamycin) - GSK
      • 6.4.9.6 Other Acne Drugs: Sales Forecast 2017-2027
  • 6.5 Acne Drugs: Market Summary

7. Dermatitis Drugs Market: Market Analysis and Forecast 2017-2027

  • 7.1 Dermatitis Drugs: High Generic Penetration
    • 7.1.1 Leading Products in the Dermatitis Drugs Market, 2016
  • 7.2 Dermatitis Drugs: Market Forecast 2017-2027
    • 7.2.1 Dermatitis Drugs: Changing Market Shares by Leading Drugs 2017-2027
  • 7.3 Leading Drugs in the Dermatitis Drugs Market
    • 7.3.1 Bepanthen (dexpanthenol)/ Bepanthol - Bayer
      • 7.3.1.1 Bepanthen: Sales Forecast 2017-2027
    • 7.3.2 Elocon (mometasone) - Merck & Co
      • 7.3.2.1 Elocon: Sales Forecast 2017-2027
    • 7.3.3 Protopic (tacrolimus) - LEO Pharma
      • 7.3.3.1 Protopic Benefits from Expanded Indication
      • 7.3.3.2 Generic Competition For Protopic
      • 7.3.3.3 Protopic: Sales Forecast 2017-2027
    • 7.3.4 Dermovate -GSK
      • 7.3.4.1 Dermovate: Sales Forecast 2017-2027
    • 7.3.5 Other Dermatitis Drugs: Sales Forecast 2017-2027
  • 7.4 Dermatitis Drugs: Market Outlook

8. Leading National Markets for Dermatological Drugs, 2017-2027

  • 8.1 The Dermatological Drugs Market by Region
    • 8.1.1 The Global Distribution of Dermatological Drugs in 2016
  • 8.2 Leading National Markets: Forecast 2017-2027
    • 8.2.1 Changing Market Shares by Region, 2016-2027
  • 8.3 Regional Dermatological Drugs Markets: Analysis and Forecasts, 2016-2027
    • 8.3.1 United States: The Largest Dermatological Drugs Market
      • 8.3.1.1 Obamacare Repeal
      • 8.3.1.2 Legislative Environment Stimulating Biosimilars Market?
      • 8.3.1.3 Biosimilar Interchangeability guidance in the US
      • 8.3.1.4 US Dermatological Drugs Market: Market Forecast 2017-2027
    • 8.3.2 The EU5 Markets: Growth Expected in Each Country
      • 8.3.2.1 EU5 Dermatological Drugs Market: Market Forecast 2017-2027
        • 8.3.2.1.1 EU5 Markets: Changing Market Shares by Country, 2016-2027
      • 8.3.2.2 Germany
        • 8.3.2.2.1 German Dermatological Drugs Market: Market Forecast 2017-2027
      • 8.3.2.3 France
        • 8.3.2.3.1 French Dermatological Drugs Market Forecast 2017-2027
      • 8.3.2.4 UK
        • 8.3.2.4.1 The Impact Of Brexit On The Dermatological Drugs Industry
          • 8.3.2.4.1.1 Pricing and Reimbursement
          • 8.3.2.4.1.2 New Regulatory Body and Clinical Trials
          • 8.3.2.4.1.3 Patent Protection
          • 8.3.2.4.1.4 Research and Funding
        • 8.3.2.4.2 UK Dermatological Drugs Market Forecast 2017-2027
      • 8.3.2.5 Italy
        • 8.3.2.5.1 Italian Dermatological Drugs Market Forecast 2017-2027
      • 8.3.2.6 Spain
        • 8.3.2.6.1 Spanish Dermatological Drugs Market Forecast 2017-2027
    • 8.3.3 Japan
      • 8.3.3.1 The Cost of Treatment in Japan
      • 8.3.3.2 Japanese Pharmaceutical Industry Regulatory Reform
      • 8.3.3.3 Japanese Dermatological Drugs Market Forecast 2017-2027
    • 8.3.4 China
      • 8.3.4.1 Expansion of Healthcare Coverage and Reimbursement in China
      • 8.3.4.2 Improving Public Perception of Dermatology in China
      • 8.4.3.3 Price Controls and the Anhui Model
      • 8.3.4.4 Chinese Dermatological Drugs Market Forecast 2017-2027
    • 8.3.5 India
      • 8.3.5.1 The Effects of the Drug Prices Control Order of 2013
      • 8.3.5.2 India's Expansion of Healthcare Provision
      • 8.3.5.3 Revised Biosimilar Guidelines
      • 8.3.5.4 Indian Dermatological Drugs Market Forecast 2017-2027
    • 8.3.6 Brazil
      • 8.3.6.1 The Growth in Brazil's Healthcare Landscape
      • 8.3.6.2 Clearer Access to Medicines in Brazil
      • 8.3.6.3 Brazilian Dermatological Drugs Market Forecast 2017-2027
    • 8.3.7 Russia
      • 8.3.7.1 Pharma2020 Strategy - Healthcare and Industry Reform
      • 8.3.7.2 Russian Dermatological Drugs Market Forecast 2017-2027
    • 8.3.8 Rest of the World
      • 8.3.8.1 The Rest of the World Dermatological Drugs Market Forecast 2017-2027

9. Leading Companies in the Dermatological Drugs Market, 2017-2027

  • 9.1 Dermatological Drugs - A Rapidly Consolidating Market
  • 9.2 Galderma (Nestle Skin Health S.A.)
    • 9.2.1 Galderma: Dermatological Drugs Portfolio, 2017
    • 9.2.2 Galderma: Recent Developments
      • 9.2.2.1 Nestlé's Acquisition of Galderma
      • 9.2.2.2 Approval and Launch of Soolantra for Rosacea
  • 9.3 Johnson & Johnson
    • 9.3.1 Johnson & Johnson: Dermatological Drugs Portfolio, 2016
    • 9.3.2 Johnson & Johnson: Dermatological Drug Development
    • 9.3.2.1 Pipeline, 2017
  • 9.4 AbbVie
    • 9.4.1 AbbVie: Dermatological Drugs Portfolio, 2017
  • 9.5 GlaxoSmithKline (GSK)
    • 9.5.1 GSK: Dermatological Drugs Portfolio, 2017
    • 9.5.3 GlaxoSmithKline (GSK): Recent Developments
    • 9.5.3.1 Business Restructuring Arrangements With Novartis
    • 9.5.4 GlaxoSmithKline (GSK): Dermatological Drugs Development Pipeline, 2016
  • 9.6 Pfizer
    • 9.6.1 Pfizer: Dermatological Drugs Portfolio, 2017
    • 9.6.2 Pfizer: Acquisition of Anacor
    • 9.6.3 Pfizer: Dermatological Drugs Development Pipeline, 2017
  • 9.7 LEO Pharma
    • 9.7.1 LEO Pharma: Dermatological Drugs Portfolio, 2017
    • 9.7.2 LEO Pharma: Dermatological Drugs Development Pipeline, 2017
    • 9.7.3 LEO Pharma: Strategic Partnership with AstraZeneca
    • 9.7.4 LEO Pharma: Acquisition of Astellas Pharma

10. Dermatological Drugs: Research and Development Pipeline, 2017-2027

  • 10.1 Innovative Products Currently in Development Will Drive Growth
    • 10.1.1 New Technology in R&D Pipeline Activities
      • 10.1.1.1 Reformulation
      • 10.1.1.2 Combination Treatments
      • 10.1.1.3 New Mechanisms and Drug Delivery Technologies
      • 10.1.1.4 Potential Market Entrants
  • 10.2 Psoriasis Drugs Development Pipeline, 2017
    • 10.2.1 Psoriasis Drugs in Phase 3 Development or Regulatory Approval Stage
      • 10.2.1.2 CF101 (Piclidenoson) - Can-Fite BioPharma
    • 10.2.2 Psoriasis Drugs in Phase 2 Development
      • 10.2.2.1 LY3009104 (baricitinib) - Incyte/ Eli Lilly
      • 10.2.2.2 PH-10 (Rose Bengal) - Provectus Biopharmaceuticals
    • 10.2.3 Psoriasis Drugs in Phase 1 and Pre-Clinical Development
  • 10.3 Skin Infection Drugs Development Pipeline, 2017
    • 10.3.1 Drugs in Phase 3 Development for Skin Infections
      • 10.3.1.1 Baxdela (delafloxacin) - Melinta Pharmaceuticals
      • 10.3.1.2 NB-001 - NanoBio Corporation
      • 10.3.1.3 Luliconazole - Topica Pharmaceuticals
    • 10.3.2 Drugs in Phase 2 Development for Skin Infections
    • 10.3.3 Drugs in Phase 1 and Preclinical Pipeline for Skin Infections
  • 10.4 Acne Drugs Development Pipeline, 2017
    • 10.4.1 Drugs in Phase 3 Development for Acne
      • 10.4.1.2 Visonac (photodynamic therapy) - Photocure
    • 10.4.2 Drugs in Phase 2 Development for Acne
    • 10.4.3 Drugs in Phase 1 and Pre-Clinical Development for Acne
    • 10.4.4 A Possible Vaccine for Acne
  • 10.5 Dermatitis Drugs Development Pipeline, 2017
    • 10.5.1 Drugs in Phase 3 Development for Dermatitis
      • 10.5.1.1 Toctino (alitretinoin) - GSK
      • 10.5.1.2 Dermadexin and Pruridexin (P3CGM) - Cipher Pharmaceuticals
      • 10.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) - Pierre Fabre
      • 10.5.1.4 REGN668/SAR231893 (dupilumab) - Regeneron/ Sanofi
    • 10.5.2 Drugs in Phase 2 Development for Dermatitis
    • 10.5.3 Drugs in Phase 1 and Preclinical Stages of Development for Dermatitis
  • 10.6 Other Dermatological Drugs Development Pipeline, 2017
    • 10.6.1 Other Dermatological Drugs: Filed or Recently Launched
      • 10.6.1.1 Actikerall (fluorouracil/salicylic acid) - Almirall
      • 10.6.1.2 Ameluz (5-ALA photodynamic therapy) - Biofrontera
      • 10.6.1.3 Mirvaso (brimonidine) - Galderma
      • 10.6.1.4 Picato (ingenol mebutate) - LEO Pharma
      • 10.6.1.5 Xolair (omalizumab) - Novartis/ Roche
    • 10.6.2 Other Dermatological Drugs: Phase 3 Pipeline Products, 2017
      • 10.6.2.1 CD5024 (ivermectin) - Galderma
      • 10.6.2.2 SR-T100 gel (Solanum incanum extract) - G&E Herbal Biotechnology
    • 10.6.3 Other Dermatological Drugs: Phase 2 Pipeline Products, 2017

11. Qualitative Analysis of the Dermatological Drugs Market, 2017-2027

  • 11.1 Market Factors Influencing Dermatological Drugs
  • 11.2 SWOT Analysis of the Global Dermatological Drugs Market, 2017-2027
    • 11.2.1 Strengths
      • 11.2.1.1 The High Unmet Clinical Need in Dermatology
      • 11.2.1.2 A Healthy Pipeline of Development-Stage Products
      • 11.2.1.3 Strong Industry-Physician Relationships
    • 11.2.2 Weaknesses
      • 11.2.2.1 Limited Efficacy and Adverse Effects May Impact Product Uptake
      • 11.2.2.2 Patient Adherence - A Major Challenge to Treatment Design
      • 11.2.2.3 Impending Patent Expiries and the Challenges Posed by Generic Competition
    • 11.2.3 Opportunities
      • 11.2.3.1 The High-Growth Sectors in Dermatology
      • 11.2.3.2 Personalised Dermatology: Technological Advances in Genomics
      • 11.2.3.3 Advances in Topical Drug Delivery Methods Offers Product Differentiation
      • 11.2.3.4 Consolidation within Dermatology - Opportunity for Synergistic Growth?
    • 11.2.4 Threats
      • 11.2.4.1 Uncertainty Surrounding Reimbursement and Payment Approvals
      • 11.2.4.2 The Rising Cost of Research and Development
      • 11.2.4.3 Downward Pressures on Drug Prices
  • 11.3 Porter's Five Force Analysis of the Global Dermatological Drugs Market, 2017-2027
    • 11.3.1 Threat of New Entrants
    • 11.3.2 Threat of Substitutes
    • 11.3.3 Rivalry among Competitors
    • 11.3.4 Power of Buyers
    • 11.3.5 Power of Suppliers

12. Research Interviews

  • 12.1 Interview with Dr Michael Siegel, Vice President of Research Programs at National Psoriasis Foundation
    • 12.1.1 National Psoriasis Foundation
    • 12.1.2 Future of the Dermatology Drugs Market
    • 12.1.3 Future Developments on Psoriatic Disease Treatment
    • 12.1.4 New Therapies Arising from Stem Cell Research
    • 12.1.5 Limitations and Scope in Developing Biomarkers for Psoriatic Disease
  • 12.2 Interveiw With Guillaume Clement, Executive Vice President, Region EUROPE+, LEO Pharma
    • 12.2.1 LEOPharma
    • 12.2.2 Future of the Dermatology Drugs Market
    • 12.2.3 Trends - Mergers and Acquisitions in the Pharmaceutical Industry
    • 12.2.4 Leo Pharma's Acquisition of Astellas Pharma
    • 12.2.5 Novel Biologic Treatments for Psoriasis, Partnership with AstraZeneca

13. Conclusions

  • 13.1 Overview of Current Market Conditions and Market Forecast, 2016-2027
  • 13.2 Leading Sectors in Dermatological Drugs in 2016
  • 13.3 Leading Regions in the Dermatological Drugs Market in 2016
  • 13.4 Future Outlook for the Various Sectors within the Dermatological Drugs Market, 2017-2027
  • 13.5 What Does the Future Hold For Dermatological Drugs?

14. Glossary

  • Associated Visiongain Reports
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain Report Evaluation Form

List of Tables

  • Table 1.1 Dermatological Drugs Market Forecast by National Markets: Revenue ($bn), AGR (%) and CAGR (%), 2017-2027
  • Table 2.1 Clinical Trial Phases, 2016
  • Table 3.1 The Global Dermatological Drugs Market by Sector: Revenue ($bn) and Market Shares (%), 2016
  • Table 3.2 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 3.3 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2016-2021, 2021-2027, 2016-2021
  • Table 3.4 The Global Dermatological Drugs Market by Sector: Market Share (%), 2016, 2021 and 2027
  • Table 4.1 Top Drugs in The Psoriasis Drugs Market: Revenue ($bn) and Market Shares (%), 2016
  • Table 4.2 Psoriasis Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.3 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2016, 2021 and 2027
  • Table 4.4 Humira Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
  • Table 4.5 Humira AbbVie Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.6 Stelara Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
  • Table 4.7 Stelara Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.8 Enbrel Historical Sales by Company: Revenue ($bn) and AGR (%), 2008-2016
  • Table 4.9 Enbrel Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.10 Remicade Historical Sales: Revenue ($bn), 2010-2016
  • Table 4.11 Remicade Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.12 Taltz: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.13 Otezla Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.14 Cosentyx Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.15 Other Psoriasis Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.1 Top Drugs in the Skin Infection Drugs Market: Revenue ($bn) and Market Share (%), 2016
  • Table 5.2 Skin Infection Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.3 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2016, 2021 and 2027
  • Table 5.4 Cubicin Sales Forecast: Revenue($bn), AGR (%) and CAGR(%), 2016-2027
  • Table 5.5 Zyvox: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014
  • Table 5.6 Zyvox: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.7 Canesten: Historical Sales: Revenue ($bn), and AGR (%), 2011-2015
  • Table 5.8 Canesten: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.9 Valtrex: Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
  • Table 5.10 Valtrex: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.11 Bactroban: Historical Sales: Revenue ($bn) and AGR (%), 2010-2013
  • Table 5.12 Bactroban Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.13 Lamisil Novartis Sales Forecast: Revenue ($bn), AGR (%), and CAGR (%), 2016-2027
  • Table 5.14 Other Skin Infection Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.1 Top Drugs in The Acne Drugs Market: Revenue ($bn) and Market Share (%), 2016
  • Table 6.2 Acne Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.3 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2016, 2021 and 2027
  • Table 6.4 Epiduo (Galderma/ Nestlé) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.5 Solodyn (Valeant) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.6 Claravis (Teva) Sales Forecast: Revenue ($bn), AGR%, and CAGR (%), 2016-2027
  • Table 6.7 Aczone (Allergan) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.8 Differin (Galderma/ Nestlé) Sales Forecast: Revenue ($bn), AGR (%) and CAGR%), 2016-2027
  • Table 6.9 Absorica/Epuris Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%),
  • 2016-2027
  • Table 6.10 Ziana Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.11 Doryx Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.12 Other Acne Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 7.1 Top Drugs in The Dermatitis Drugs Market: Revenue ($bn) and Market Share (%), 2016
  • Table 7.2 Dermatitis Drugs Market: Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 7.3 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2016, 2021, 2027
  • Table 7.4 Bepanthen/Bepanthol Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 7.5 Elocon Sales Forecast: Revenue ($bn), AGR (%) CAGR (%), 2016-2027
  • Table 7.6 Protopic Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 7.7 Dermovate Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 7.8 Other Dermatitis Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.1 The Global Dermatological Drugs Market by Region: Market Size ($bn) and Market Share (%), 2016
  • Table 8.2 Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2016-2027
  • Table 8.3 The Global Dermatological Drugs Market Forecast by Region: CAGR (%), 2016-2021, 2021-2027, and 2016-2027
  • Table 8.4 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2016, 2021 and 2027
  • Table 8.5 The US Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.6 US Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.7 The EU5 Dermatological Drugs Market by Country Revenue ($bn) and Market Share (%), 2016
  • Table 8.8 The EU5 Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.9 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2016, 2021 and 2027
  • Table 8.10 The German Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.11 The German Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.12 The French Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.13 The French Dermatological Drugs Market Forecast: Revenue ($bn, AGR (%)and CAGR (%), 2016-2027
  • Table 8.14 The UK Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.15 The UK Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.16 The Italian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.17 The Italian Dermatological Drugs Market Forecast: ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.18 The Spanish Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.19 The Spanish Dermatological Drugs Market Forecast: Revenue($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.20 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.21 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.22 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.23 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn, AGR (%) and CAGR (%), 2016-2027
  • Table 8.24 The Indian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.25 The Indian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.26 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.27 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.28 The Russian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.29 The Russian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.30 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn), Market Share (%) and CAGR (%), 2016-2027
  • Table 8.31 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 9.1 Galderma: Company Overview, 2016
  • Table 9.2 Johnson & Johnson: Company Overview, 2016
  • Table 9.3 AbbVie: Company Overview, 2017
  • Table 9.4 GlaxoSmithKline: Company Overview, 2016
  • Table 9.5 GlaxoSmithKline: Dermatological Drugs Pipeline, 2016
  • Table 9.6 Pfizer: Company Overview, 2016
  • Table 9.7 LEO Pharma: Company Overview, 2016
  • Table 10.1 Psoriasis Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.2 Psoriasis Drugs Pipeline: Phase 2 Drugs, 2016
  • Table 10.3 Psoriasis Drugs Pipeline: Phase 1 and Pre-Clinical Drugs, 2016
  • Table 10.4 Skin Infections Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.5 Skin Infections Drugs Pipeline: Phase 2 Drugs, 2016
  • Table 10.6 Acne Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.7 Acne Drugs Pipeline: Phase 2 Drugs, 2015
  • Table 10.8 Dermatitis Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.9 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2016
  • Table 10.10 Other Dermatological Drugs Pipeline: Filed or Recently Launched Drugs, 2016
  • Table 10.11 Other Dermatological Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.12 Other Dermatological Drugs Pipeline: Phase 2 Drugs, 2016
  • Table 11.1 SWOT Analysis of the Global Dermatological Drugs Market, 2016-2026
  • Table 12.1 Global Dermatological Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2016, 2021 and 2027
  • Table 12.2 The Global Dermatological Drugs Market by Sector: Market Size ($bn) and Market Shares (%), 2016
  • Table 12.3 The Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), 2016, 2021 and 2027
  • Table 12.4 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), 2016, 2021, 2027

List of Figures

  • Figure 1.1 Global Dermatological Drugs Market: Market Sectors, 2017
  • Figure 2.1 Anatomy of Human Skin
  • Figure 3.1 The Global Dermatological Drugs Market by Sector: Revenue ($bn), 2016
  • Figure 3.2 The Global Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%) 2016-2027
  • Figure 3.3 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2016-2021
  • Figure 3.4 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2021-2027
  • Figure 3.5 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2016-2027
  • Figure 3.6 The Global Dermatological Drugs Market by Sector: Market Share (%), 2016
  • Figure 3.7 The Global Dermatological Drugs Market by Sector: Market Share (%), 2021
  • Figure 3.8 The Global Dermatological Drugs Market by Sector: Market Share (%), 2027
  • Figure 4.1 Top Drugs in The Psoriasis Drugs Market: Revenue ($bn), 2016
  • Figure 4.2 Psoriasis Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.3 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2016
  • Figure 4.4 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%) by Leading Drugs, 2021
  • Figure 4.5 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2027
  • Figure 4.6 Humira Historical Sales: Revenue ($bn) AGR (%), 2010-201
  • Figure 4.7 Humira AbbVie Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.8 Stelara Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
  • Figure 4.9 Stelara Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.10 Enbrel Historical Sales by Company: Revenue ($bn), 2008-2015
  • Figure 4.11 Enbrel Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.12 Remicade Historical Sales: Revenue ($bn) and AGR (%), 2008-2016
  • Figure 4.13 Remicade Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.14 Taltz Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.15 Otezla Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.16 Cosentyx Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.17 Other Psoriasis Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.1 Top Drugs in the Skin Infection Drugs Market: Revenue ($bn), 2016
  • Figure 5.2 Skin Infection Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.3 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2016
  • Figure 5.4 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2021
  • Figure 5.5 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2027
  • Figure 5.6 Cubicin Sales Forecast: Revenue ($bn) AGR (%), 2016-2027
  • Figure 5.7 Zyvox: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014
  • Figure 5.8 Zyvox: Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.9 Canesten: Historical Sales: Revenue ($bn) and AGR (%), 2011-2014
  • Figure 5.10 Canesten: Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.11 Valtrex: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014
  • Figure 5.12 Valtrex Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.13 Bactroban: Historical Sales: Revenue ($bn) AGR (%), 2010-2013
  • Figure 5.14 Bactroban Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.15 Lamisil Novartis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.16 Other Skin Infection Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.1 Top Drugs in The Acne Drugs Market: Revenue ($bn), 2016
  • Figure 6.2 Acne Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.3 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2016
  • Figure 6.4 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2021
  • Figure 6.5 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2027
  • Figure 6.6 Epiduo (Galderma/ Nestlé) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.7 Solodyn (Valeant) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.8 Claravis (Teva) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.9 Aczone (Allergan) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.10 Differin (Galderma/ Nestlé) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.11 Absorica/Epuris Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.12 Ziana Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.13 Doryx Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.14 Other Acne Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.1 Top Drugs in The Dermatitis Drugs Market: Revenue ($bn), 2016
  • Figure 7.2 Dermatitis Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.3 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2016
  • Figure 7.4 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2021
  • Figure 7.5 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2027
  • Figure 7.6 Bepanthen/ Bepanthol Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.7 Elocon Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.8 Protopic Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.9 Dermovate Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.10 Other Dermatitis Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 8.1 The Global Dermatological Drugs Market by Region: Market Size ($bn), 2016
  • Figure 8.2 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2016
  • Figure 8.3 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2021
  • Figure 8.4 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2027
  • Figure 8.5 US Dermatological Drugs Market Forecast: Revenue ($bn) AGR (%), 2016-2027
  • Figure 8.6 The EU5 Dermatological Drugs Market by Country: Revenue ($bn), 2016
  • Figure 8.7 Germany, France, UK, Italy, and Spain Dermatological Drugs Market Forecast: Revenue ($bn), 2016-2027
  • Figure 8.8 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2016
  • Figure 8.9 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2021
  • Figure 8.10 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2027
  • Figure 8.11 The German Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.12 The French Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.13 The UK Dermatological Drugs Market: Market Forecast ($m, AGR%), 2016-2027
  • Figure 8.14 The Italian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.15 The Spanish Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.16 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.17 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.18 The Indian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.19 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.20 The Russian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.21 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 11.1 Porter's Five Force Analysis of the Dermatological Drugs Market, 2016
  • Figure 12.1 Global Dermatological Drugs Market Forecast: Revenue ($bn), 2016, 2021, 2027
  • Figure 12.2 The Global Dermatological Drugs Market by Sector: Market Size ($bn), 2016
  • Figure 12.3 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), 2016, 2021, 2027

Companies Listed

  • Abbott
  • AbbVie
  • Actavis
  • AET BioTech
  • Alkem Laboratories
  • Allergan
  • Almirall
  • Amgen
  • Anacor
  • Ascend Therapeutics
  • Astellas
  • Aurovindo
  • Barr Labs
  • Bayer
  • Betta Pharmaceuticals
  • Biocon/Mylan
  • Biofrontera
  • Biogen
  • Biovail Laboratories
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Brazilian Society of Dermatology
  • Cadila Healthcare
  • Can-Fite BioPharma
  • Cassiopea SpA
  • Celgene
  • Celltrion
  • Cempra
  • Cipher Pharmaceuticals
  • Cipla
  • Cubist Pharmaceuticals
  • Cutanea Life Sciences
  • Dow Pharmaceuticals Science
  • Dr Reddy's
  • Durata Therapeutics
  • Eisai
  • Eli Lilly
  • European Medicines Agency (EMA)
  • European Pharmaceutical Market Research Association (EPhMRA)
  • Food and Drug Association (FDA)
  • Foamix
  • Fougera
  • Fujifilm
  • G&E Herbal Biotechnology
  • Galderma
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Heritage
  • Impax
  • Incyte
  • Janssen Biotech
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • L'Oreal
  • LEO Pharma
  • Lupin
  • Maruho
  • Mayne Pharma
  • Medicis
  • Medison Pharma
  • Melinta Pharmaceuticals
  • Merck
  • Merz Pharmaceuticals
  • Mitsubishi Tanabe
  • MorphoSys
  • Mylan
  • NanoBio Corporation
  • National Psoriasis Foundation (NPF)
  • NeoStrata Compnay Inc
  • Nestle Skin Health
  • Novan
  • Novartis
  • Perriogo
  • Pfizer
  • PharmaPraxis
  • Photocure
  • Pierre Fabre
  • Provectus Biopharmaceuticals
  • QLT Inc
  • Ranbaxy
  • Regeneron Pharmaceuticals
  • Roche
  • Samsung Bioepis
  • Samsung BioLogics
  • Sandoz
  • Sanofi
  • Schering-Plough
  • Shanghai CP Buojian Pharmaceutical
  • Sidmak Labs
  • Sol-Gel Technologies Ltd
  • Sun Pharma
  • Sunovion
  • Takeda
  • Tanabe
  • Tanja Todberg
  • Taro Pharmaceuticals
  • Teva
  • Thesan Pharmaceuticals Inc
  • Topica Pharmaceuticals
  • UCB
  • Valeant
  • Vical
  • Warner Chilcott
  • Watson Pharmaceuticals
  • Xenon Pharmaceuticals
  • Zydus
Back to Top